Baeocystin and Norbaeocystin: Minor Tryptamines

Psilocybin Mushroom Chemistry

2 compounds, minimal data

Baeocystin and norbaeocystin are phosphorylated tryptamines found alongside psilocybin in psychedelic mushrooms. Despite decades of detection in mushroom tissue, their pharmacology was first systematically studied only in 2020.

Sherwood et al., Journal of Natural Products, 2020

N-demethyl

baeocystin differs from psilocybin by one methyl group

No head twitch

baeocystin did not produce psychedelic marker in mice

5-HT2A active

dephosphorylated metabolites bind the serotonin 2A receptor

Sherwood et al., Journal of Natural Products, 2020

View as image ↗

Psilocybin mushrooms contain more than psilocybin. Baeocystin and norbaeocystin are structurally related phosphorylated tryptamines present in most Psilocybe species, typically at lower concentrations than psilocybin. Their existence has been known since the 1960s, but their actual pharmacological effects were first systematically tested only in 2020, when Sherwood et al. synthesized pure forms and evaluated them in receptor binding assays and cellular functional screens.^[1] The question of whether these compounds contribute meaningfully to the subjective mushroom experience remains partially unanswered. For the wider context of mushroom alkaloid chemistry, see beyond psilocybin: the full chemical profile of psychedelic mushrooms. For the related compound aeruginascin, see aeruginascin: the compound that may make some mushrooms "friendlier".

The core issue is that most research on psilocybin mushrooms has used purified psilocybin, ignoring the minor alkaloids entirely. Whether consuming whole mushrooms produces effects different from purified psilocybin, and whether baeocystin and norbaeocystin explain any such difference, are questions with very limited experimental data.

Chemistry: one methyl group at a time

The structural relationships among these compounds follow a simple pattern of progressive demethylation at the nitrogen atom on the tryptamine side chain.

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) carries two methyl groups on its nitrogen. Baeocystin (4-phosphoryloxy-N-methyltryptamine) has one methyl group removed. Norbaeocystin (4-phosphoryloxytryptamine) has both methyl groups removed. All three share the same 4-phosphoryloxy indole core that defines this alkaloid family.^[1]

Like psilocybin, both compounds are prodrugs. They require enzymatic dephosphorylation (removal of the phosphate group) to become pharmacologically active. Psilocybin becomes psilocin; baeocystin becomes norpsilocin; norbaeocystin becomes 4-hydroxytryptamine. Alkaline phosphatase in the gut and liver performs this conversion. The rate and completeness of this dephosphorylation may differ between compounds, which would affect their bioavailability, but this has not been measured for baeocystin or norbaeocystin in any organism.^[2]

Gotvaldova et al. (2021) tracked the stability of all four compounds (psilocybin, psilocin, baeocystin, norbaeocystin) in Psilocybe cubensis biomass under different storage conditions. All four degraded over time, with psilocin being the least stable. Baeocystin and norbaeocystin showed stability profiles similar to psilocybin, suggesting they persist in dried mushroom material at roughly the same rate.^[3]

Receptor binding: similar but not identical

Sherwood et al. (2020) conducted the first comprehensive receptor binding screen for baeocystin, norbaeocystin, norpsilocin, and aeruginascin. The study synthesized pure forms of each compound and tested them against a panel of serotonin receptors and the serotonin transporter (SERT).^[1]

Norpsilocin (baeocystin's active metabolite) showed potent agonist activity at 5-HT2A, the receptor primarily responsible for psychedelic effects. Its binding affinity was comparable to psilocin. It also showed activity at 5-HT2B, 5-HT2C, and several 5-HT1 subtypes. The receptor profile overlapped substantially with psilocin but was not identical.^[1]

Glatfelter et al. (2022) extended this work with a more detailed structure-activity relationship study. They measured both binding affinity and functional activity (calcium mobilization, beta-arrestin recruitment) across multiple serotonin receptor subtypes. Baeocystin itself (before dephosphorylation) inhibited binding at fewer receptors than psilocybin, showing affinity primarily for 5-HT1B, 5-HT1D, 5-HT2B, and 5-HT7a. Critically, the phosphorylated forms (baeocystin and psilocybin) showed weak 5-HT2A binding, confirming that dephosphorylation is required for psychedelic receptor engagement.^[2]

The implication: if baeocystin is efficiently dephosphorylated to norpsilocin in vivo, it should activate 5-HT2A. But "should" and "does" are different questions, as the behavioral data revealed.

Behavioral pharmacology: the head-twitch test

The head-twitch response (HTR) in mice is the most widely used behavioral proxy for psychedelic activity. Compounds that activate 5-HT2A receptors in the brain produce this distinctive rapid head movement, and its frequency correlates with subjective psychedelic intensity in humans across known psychedelics.

Rakoczy et al. (2024) published the most comprehensive behavioral study of mushroom tryptamines to date, testing psilocybin, baeocystin, norbaeocystin, norpsilocin, and aeruginascin in rats. The results were clear but surprising: only psilocybin produced robust head-twitch responses. Baeocystin and norbaeocystin did not, even at doses comparable to active psilocybin doses on a molar basis.^[4]

The study also measured blood-brain barrier penetration using an in vitro mimetic. Dephosphorylated metabolites of both baeocystin (norpsilocin) and norbaeocystin (4-hydroxytryptamine) crossed the barrier model to a degree similar to psilocin. This suggests the compounds can reach the brain, but once there, they do not produce classic psychedelic behavioral responses.^[4]

Glatfelter et al. (2022) reached a similar conclusion: baeocystin produced "minimal" head-twitch responses in mice compared to psilocybin.^[2]

The disconnect between in vitro 5-HT2A activation and in vivo behavioral silence is not fully explained. Possible explanations include: differences in receptor efficacy (partial versus full agonism), differences in receptor kinetics (how long the compound occupies the receptor), differences in metabolism speed, or engagement of inhibitory receptor subtypes that counteract the 5-HT2A signal. For more on how 5-HT2A engagement relates to psychedelic response, see 5-HT2A receptor density and psilocybin response.

Non-psychedelic therapeutic signals

The Rakoczy et al. (2024) study included a forced swim test (FST), a standard rodent behavioral assay used to screen for antidepressant-like activity. In this test, rats are placed in a water cylinder, and the time spent immobile (floating without active swimming or climbing) is measured. Antidepressant compounds typically reduce immobility time.

Norbaeocystin reduced immobility in the forced swim test to a degree comparable to psilocybin, even though it did not produce head-twitch responses.^[4] This dissociation between psychedelic and antidepressant-like effects is consistent with a broader pharmacological debate about whether the therapeutic benefits of psilocybin require the subjective psychedelic experience or can be achieved through receptor activation without perceptual changes.

Sherwood et al. (2024) followed up with norpsilocin analogs, demonstrating that structural modifications to the norpsilocin scaffold could produce compounds with varying ratios of psychedelic-like to antidepressant-like activity.^[5] This medicinal chemistry approach uses baeocystin's metabolite as a starting point for designing non-hallucinogenic therapeutics, an active area of pharmaceutical development.

These findings are from a single rat study for norbaeocystin and should not be overinterpreted. The forced swim test is a screening tool with known limitations (false positives, strain dependence, sensitivity to sedation), not a definitive measure of antidepressant potential.

How much is actually in the mushroom?

The question of whether baeocystin and norbaeocystin matter to the mushroom experience depends partly on how much is present in consumed material.

Goff et al. (2024) analyzed psilocybin, psilocin, baeocystin, and norbaeocystin in multiple Psilocybe cubensis strains using liquid chromatography. Baeocystin concentrations ranged from 0.14 to 0.88 mg/g dry weight. Norbaeocystin was present at lower levels, typically 0.04 to 0.16 mg/g. For comparison, psilocybin ranged from 4.0 to 12.0 mg/g in the same samples.^[6]

At these ratios, a typical 2-gram dried mushroom dose would deliver roughly 8-24 mg of psilocybin but only 0.3-1.8 mg of baeocystin and 0.08-0.32 mg of norbaeocystin. Given that baeocystin shows minimal psychedelic activity at the doses tested in animals, these quantities are unlikely to produce independent psychedelic effects.

Jensen et al. (2006) noted that species other than P. cubensis may have different alkaloid ratios. Inocybe aeruginascens, for example, contains aeruginascin alongside psilocybin but was not analyzed for baeocystin in that study.^[7] Species-level variation in minor tryptamine content could explain anecdotal reports of qualitatively different experiences from different mushroom species, but this hypothesis has not been tested experimentally.

Strain variation within P. cubensis adds another layer of complexity. Goff et al. (2024) found that some strains contained six times more baeocystin than others (0.14 vs 0.88 mg/g).^[6] Growth conditions, harvest timing, and drying methods also affect alkaloid ratios. Gotvaldova et al. (2021) showed that all four alkaloids degrade during storage, but at different rates, meaning the baeocystin-to-psilocybin ratio in consumed material may differ from the ratio in freshly harvested mushrooms.^[3] These variables make it difficult to standardize or even characterize the alkaloid exposure from any given mushroom dose.

The entourage effect question

Cannabis research popularized the "entourage effect" concept: the idea that minor compounds modulate the effects of the primary active ingredient. Some mushroom researchers and advocates have proposed a parallel "entourage effect" for psilocybin mushrooms, in which baeocystin, norbaeocystin, aeruginascin, and other minor alkaloids collectively modify the psilocybin experience.

The current evidence does not support this hypothesis, but neither does it rule it out. What the data actually shows:

Baeocystin alone does not produce psychedelic behavior in rodents at tested doses. Norbaeocystin alone does not produce psychedelic behavior but does show antidepressant-like activity. Neither compound has been tested in combination with psilocybin in any published study. The combination question, which is the actual entourage hypothesis, remains completely untested.^[4]

No controlled human study has compared the effects of pure psilocybin against whole mushroom extract containing the full alkaloid profile. Without this comparison, the entourage effect in mushrooms remains a speculation drawn by analogy from cannabis, not an observation from mushroom pharmacology. For a deeper exploration of whether this effect exists, see the entourage effect in magic mushrooms.

Conflicting historical reports

The sparse human evidence on baeocystin consists of two anecdotal reports that directly contradict each other.

Jochen Gartz, a German mycologist, reported in the 1990s that 10 mg of pure baeocystin produced psychoactive effects comparable to 10 mg of psilocybin. Paul Stamets, an American mycologist, later reported that 10 mg of pure baeocystin produced no hallucinogenic effects, though he noted pupil dilation and apparent anxiolysis (anxiety reduction).

Neither report was a controlled study. Both were single-person, unblinded observations without placebo comparison, dose verification, or standardized outcome measures. They are historical curiosities, not data. The rodent behavioral studies from Glatfelter et al. (2022) and Rakoczy et al. (2024) are far more informative, and they align more closely with Stamets' observation of minimal psychedelic activity.^[2][4]

The Bottom Line

Baeocystin and norbaeocystin are phosphorylated tryptamines present at low concentrations in most psilocybin mushrooms. Their dephosphorylated metabolites activate the 5-HT2A serotonin receptor in vitro, but neither compound produces psychedelic-like behavioral responses in rodent models at the doses tested. Norbaeocystin shows antidepressant-like activity in the forced swim test without psychedelic markers, suggesting potential non-hallucinogenic therapeutic value. Whether these compounds meaningfully contribute to the subjective effects of whole mushroom consumption has not been experimentally tested through combination studies.

Frequently Asked Questions

Is baeocystin psychoactive?

In rodent behavioral studies, baeocystin did not produce head-twitch responses (the standard proxy for psychedelic activity) at doses comparable to psychoactive psilocybin doses (Glatfelter et al., 2022; Rakoczy et al., 2024). Its dephosphorylated metabolite, norpsilocin, activates the 5-HT2A serotonin receptor in vitro with potency similar to psilocin, but this receptor activation does not translate to psychedelic-like behavior in animals.

What is the difference between baeocystin and psilocybin?

Baeocystin is the N-demethylated analog of psilocybin: it has one methyl group removed from the nitrogen atom on the tryptamine side chain. This single structural difference changes receptor binding affinity and behavioral pharmacology. Baeocystin binds fewer serotonin receptor subtypes than psilocybin and does not produce psychedelic behavior in rodent models (Glatfelter et al., 2022).

How much baeocystin is in magic mushrooms?

In Psilocybe cubensis, baeocystin ranges from 0.14 to 0.88 mg/g dry weight, while psilocybin ranges from 4.0 to 12.0 mg/g (Goff et al., 2024). Baeocystin typically represents 5-15% of total alkaloid content. A standard 2-gram dried dose would contain roughly 0.3-1.8 mg of baeocystin compared to 8-24 mg of psilocybin.

Does norbaeocystin have antidepressant effects?

In one rat study, norbaeocystin reduced immobility in the forced swim test (a screening assay for antidepressant-like activity) to a degree comparable to psilocybin, without producing head-twitch responses (Rakoczy et al., 2024). This suggests potential non-hallucinogenic antidepressant activity. However, this is a single animal study using a screening tool with known limitations.

Do minor tryptamines create an entourage effect in mushrooms?

The entourage effect hypothesis for psilocybin mushrooms has not been experimentally tested. No published study has compared the effects of pure psilocybin against psilocybin combined with baeocystin and norbaeocystin. The individual compounds show minimal psychedelic activity alone (Rakoczy et al., 2024), but their combined effect with psilocybin remains unknown.

What is norpsilocin and how does it relate to baeocystin?

Norpsilocin is the dephosphorylated (active) metabolite of baeocystin, just as psilocin is the active metabolite of psilocybin. Alkaline phosphatase enzymes remove the phosphate group to produce norpsilocin, which then binds serotonin receptors. Norpsilocin shows potent 5-HT2A agonist activity in cell assays comparable to psilocin (Sherwood et al., 2020) but does not produce psychedelic-like behavior in rats.

Sources & References

1. 1RTHM-00654·Sherwood, Alexander M et al. (2020). “Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin..” Journal of natural products.Study breakdown →PubMed →↩
2. 2RTHM-00759·Glatfelter, Grant C et al. (2022). “Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice..” ACS pharmacology & translational science.Study breakdown →PubMed →↩
3. 3RTHM-00688·Gotvaldová, Klára et al. (2021). “Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis..” Drug testing and analysis.Study breakdown →PubMed →↩
4. 4RTHM-00901·Rakoczy, Ryan J et al. (2024). “Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms..” British journal of pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-00908·Sherwood, Alexander M et al. (2024). “Psychedelic-like Activity of Norpsilocin Analogues..” ACS chemical neuroscience.Study breakdown →PubMed →↩
6. 6RTHM-00879·Goff, Roman et al. (2024). “Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry..” Analytica chimica acta.Study breakdown →PubMed →↩
7. 7RTHM-00101·Jensen, Niels et al. (2006). “Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens..” Planta medica.Study breakdown →PubMed →↩